Waterloo Capital L.P. Acquires 506 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Waterloo Capital L.P. lifted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 11.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,865 shares of the medical equipment provider’s stock after acquiring an additional 506 shares during the quarter. Waterloo Capital L.P.’s holdings in Intuitive Surgical were worth $2,539,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Atala Financial Inc bought a new position in Intuitive Surgical during the fourth quarter worth $25,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $26,000. BankPlus Trust Department acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Hurley Capital LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter worth about $28,000. Finally, Summit Securities Group LLC acquired a new position in Intuitive Surgical in the 4th quarter valued at about $30,000. 83.64% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Brian Edward Miller sold 8,900 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the transaction, the executive vice president now directly owns 5,758 shares in the company, valued at approximately $2,793,033.06. This represents a 60.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 11,545 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total value of $5,763,494.90. Following the sale, the executive vice president now directly owns 5,224 shares in the company, valued at approximately $2,607,925.28. This trade represents a 68.85 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,754 shares of company stock worth $17,691,621. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ISRG shares. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Citigroup lifted their price target on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. CICC Research assumed coverage on Intuitive Surgical in a report on Monday, January 27th. They issued a “neutral” rating and a $550.00 price objective on the stock. Erste Group Bank downgraded Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a report on Monday, March 17th. Finally, JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $611.86.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $451.58 on Friday. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The firm has a market cap of $160.84 billion, a price-to-earnings ratio of 70.45, a PEG ratio of 5.85 and a beta of 1.55. The business’s fifty day moving average is $545.18 and its 200-day moving average is $532.64.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.